ECDC and EMCDDA technical guidance on prevention and control of infectious diseases among people who inject drugs
The content of this joint guidance was developed by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) with the support of a technical advisory group composed of policy makers, service providers, civil society representatives and preventative health experts from throughout the EU/EEA.
ECDC and EMCDDA technical guidance on prevention and control of infectious diseases among people who inject drugs - guidance in brief
This evidence-based guidance is designed to inform the development, monitoring and evaluation of national strategies and programmes in countries in Europe in order to reduce and prevent infections among people who inject drugs.
Risk assessment on xenotropic murine leukemia virus-related virus (XMRV) and its implications for blood donation
ECDC plays an important role in providing its stakeholders with scientific advice when requested. On 23 September 2010 ECDC received such a request from the European Commission’s DG SANCO (Directorate C – Public Health and Risk Assessment).
Joint ECDC and EMCDDA rapid risk assessment: HIV in injecting drug users in the EU/EEA, following a reported increase of cases in Greece and Romania
Most European countries reported no changes in the rate of newly diagnosed cases of HIV or HIV prevalence in IDU in 2011.
Risk assessment of HTLV-I/II transmission by tissue/cell transplantation
Following a request from the European Commission in August 2010, ECDC assessed the epidemiological history of Human T-lymphotropic Virus (HTLV) across the world, possible risks of HTLV transmission through transplantation of human tissues and cells, and possible measures to prevent such transmission.
Evaluating HIV treatment as prevention in the European context
Despite efforts to prevent new HIV infections, more than 27 000 people were newly diagnosed with HIV in the European Union (EU) and the European Economic Area (EEA) in 2010.
Risk assessment on change of testing requirements for partner donation of reproductive cells
In May 2011, the European Commission asked ECDC to estimate the change in total exposure risk to hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency virus (HIV) during reproductive cell handling and storage for secondary parties, if the current scheme of testing at each cell donation would change to testing partner donors of reproductive cells once or twice a year.
Technical guidance on the Introduction of HPV vaccines in European Union countries – an update
In January 2008, a panel of ECDC experts produced the Guidance for the introduction of HPV vaccines in EU countries. Since then, the European Union has come a long way: most countries have implemented national vaccination programmes for adolescent girls and a significant number have also introduced catch-up programmes for young women.
Public health guidance on HIV and STI prevention among men who have sex with men
This guidance, based on a systematic review of the literature and expert opinion, suggests that there is good evidence to ensure that some key components are considered for inclusion in national and sub-national public health programmes in countries in Europe.